Baxter Says Generic Co. Infringed Hypertension Med Patent

Law360, Los Angeles (October 22, 2013, 3:41 PM EDT) -- Baxter International Inc. on Tuesday hit HQ Specialty Pharma Corp. with a lawsuit in New Jersey federal court alleging HQ's proposed generic version of its blood pressure and heart rhythm disorder drug Brevibloc infringes two of its patents. 

In its complaint, Deerfield, Ill.-based Baxter alleges Paramus, N.J.-based HQ's submission to the Food and Drug Administration of a new drug application for a generic version of Brevibloc constitutes infringement of its U.S. Patent Numbers 6,310,094 and 6,528,540. 

"Baxter has no adequate remedy at law for HQ Specialty...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.